After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. After-hours trades for Novavax Inc. (NVAX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.07, or 1.07%, to $6.64. The Novavax Inc. has recorded 96,655 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Novavax to Participate in TD Cowen’s 43rd Annual Health Care Conference.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Stocks Info
As a NASDAQ listed company, NVAX falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $6.57 and fluctuated between $6.95 as its day high and $6.55 as its day low. The current market capitalization of Novavax Inc. is $510.23M. A total of 3.78 million shares were traded on the day, compared to an average of 7.67M shares.
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, NVAX has seen 4 BUY and 4 SELL insider trades, representing the acquisition of 13,766 and the disposition of 4,826 shares. Over the last 12 months, there were 20 BUYs and 16 SELLs from insiders. Insiders purchased 40,778 shares during that period but sold 25,586.
In the most recent transaction, YOUNG JAMES F sold 12,500 shares of NVAX for 73.58 per share on Mar 31. After the transaction, the Director now owns 62,590 company shares.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for NVAX in the last 3 months, the mean price target is $50.80 with high estimates of $110.00 and low estimates of $10.00. In terms of 52-week highs and lows, NVAX has a high of $85.60 and a low of $6.64.
As of this writing, NVAX has an earnings estimate of -$1.12 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.42 per share and a lower estimate of -$1.85. The company reported an EPS of -$6.53 in the last quarter, which was -218.70% lower than expectations of $5.5.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NVAX is Overweight with a score of 3.50. A total of 3 analysts rated the stock as Buy while 0 rated it as Overweight while 1 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.
